The massive $100M ATM (1.4x market cap) signals acute capital needs for a pre-revenue biotech with no approved products. Expect heavy downward pressure as shares hit the market. Monitor daily volume and Jefferies selling activity. The 10-Q likely shows a short cash runway — this is a desperation raise, not opportunistic. Short sellers should watch for accelerated selling.
Price Chart
Executive Summary
Spero Therapeutics filed a universal shelf registration statement (S-3) to register up to $300M in securities, including an immediate $100M at-the-market (ATM) common stock offering via Jefferies. The filing comes 16 days after a 10-Q showing a $70M market cap and a clinical-stage biotech with no approved products, making the ATM size (1.4x market cap) massively dilutive. This is a desperation capital raise to fund development of SP001, a preclinical CD40L antibody licensed from Innovent, with no near-term revenue prospects.
Key Financial Metrics
Key Facts
- S-3 registers up to $300M in securities (debt, common, preferred, warrants, units).
- Includes an immediate $100M ATM common stock offering via Jefferies (3% commission).
- ATM size ($100M) is ~143% of current $70M market cap — extreme potential dilution.
- Stock at $1.21/share; 58.1M shares outstanding as of June 30, 2026; ATM could add up to 82.6M shares.
- Company is a clinical-stage biopharma with no approved products; lead candidate SP001 is preclinical.
- 10-Q filed 16 days prior shows no revenue from product sales; company is pre-revenue.
- Proceeds for 'general corporate purposes' including clinical trials, R&D, working capital.
- Historical performance shows avg -14% T+20 return on prior SPRO reports; model has over-scored this ticker.
Financial Impact
Up to $100M in gross proceeds from ATM, representing ~143% dilution of current $70M market cap at $1.21/share.
Risk Factors
- Extreme dilution: ATM could increase share count by ~140% from 58.1M to ~141M shares.
- Pre-revenue clinical-stage company with no approved products; SP001 is still preclinical.
- Historical SPRO reports show avg -14% T+20 return; model has consistently over-scored this ticker.
- No analyst bullish sentiment (0% buy ratings); 3 hold, 1 sell, 2 strong sell.
- Management has broad discretion over proceeds; no specific use-of-proceeds plan disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (SPRO) — Batch item 1 | 0001193125-26-374702 |
| Document: 0001193125-26-374702-index.html | 0001193125-26-374702 |
| Document: 0001193125-26-374702.txt | 0001193125-26-374702 |
| S-3 Filing (SPRO) — Batch item 4 | 0001193125-26-374702 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.20 (−5.75%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 28, 2026 4w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.20 (−3.63%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.20 (−47.12%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.20 (−44.42%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.20 (−43.36%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.20 (−56.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access